A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients



Status:Completed
Conditions:Colitis, Colitis, Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:Any
Updated:7/8/2018
Start Date:August 31, 2004
End Date:September 9, 2015

Use our guide to learn which trials are right for you!

A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis

The purpose of this study is to evaluate long-term safety information of infliximab in
patients who have participated in infliximab clinical studies in ulcerative colitis.

This is a long term, multicenter, international safety study to evaluate targeted long-term
safety information on patients who have participated in infliximab(Remicade) clinical studies
in ulcerative colitis that require long-term safety follow-up. All patients who received at
least one dose of study drug (infliximab or placebo) in the primary studies (C0168T37
,C0168T46, C0168T72) are eligible to participate in this long-term safety follow-up study
(C0168T62). Patients will begin participation in C0168T62 at the time of their last safety
visit in the primary study and will be followed for 5 years. No study agent will be
administered. Information on deaths, serious infections, new malignancies (including
colorectal cancer) and new autoimmune diseases and surgical procedures (including colectomy)
and hospitalizations for the treatment of ulcerative colitis will be collected. Information
about possible delayed allergic reactions (possible fever, rash, fatigue, joint pain) will
also be collected if patients received infliximab after the end of the primary study. In
addition, data on dysplasia of the colon will be collected from patients who were identified
in the primary study to be at high-risk for colon cancer and were required per protocol to
undergo a follow-up colonoscopy as part of long-term safety follow-up. All adverse events,
including non-serious adverse events, will also be collected.

Inclusion Criteria:

- All patients enrolled in three Phase 3 Janssen-sponsored (C0168T37, C0168T46,
C0168T72) infliximab clinical studies in ulcerative colitis that require long-term
safety follow-up

- Patients must have received at least 1 dose of study agent to be eligible for
participation in the study

Exclusion Criteria:

- Patients who refuse consent or are unwilling to respond to requests for long-term safety
information within the required timeframe will be excluded. In addition, patients
participating in a study extension to the primary study are not eligible for participation
in the C0168T62 study during the study extension participation
We found this trial at
45
sites
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
?
mi
from
Asheville, NC
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Beaver Falls, PA
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Burlington, VT
Click here to add this to my saved trials
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
Egg Harbor Township, New Jersey 08234
?
mi
from
Egg Harbor Township, NJ
Click here to add this to my saved trials
?
mi
from
Federal,
Click here to add this to my saved trials
?
mi
from
Great Neck, NY
Click here to add this to my saved trials
?
mi
from
Hartford, CT
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Laurel, MD
Click here to add this to my saved trials
?
mi
from
Lexington, KY
Click here to add this to my saved trials
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Memphis, TN
Click here to add this to my saved trials
?
mi
from
Metairie, LA
Click here to add this to my saved trials
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Oakland, CA
Click here to add this to my saved trials
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Plymouth, MN
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Providence, RI
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Rochester, NY
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials